TY - JOUR
T1 - Comparative analysis of cholera serum vibriocidal antibodies from Convalescent and vaccinated adults in Zambia
AU - Ng'ombe, Harriet
AU - Bosomprah, Samuel
AU - Phiri, Bernard
AU - Muchimba, Mutinta
AU - Liswaniso, Fraser
AU - Chibuye, Mwelwa
AU - Luchen, Charlie Chaluma
AU - Chibesa, Kennedy
AU - Musukuma-Chifulo, Kalo
AU - Mwape, Kapambwe
AU - Tigere, Sekayi
AU - Silwamba, Suwilanji
AU - Sinkala, Annel
AU - Simuyandi, Michelo
AU - Mbewe, Nyuma
AU - Kapaya, Fred
AU - Cunningham, Adam F.
AU - Chilengi, Roma
AU - Sack, David
AU - Chisenga, Caroline Cleopatra
N1 - Publisher Copyright:
© 2024 Elsevier Ltd
PY - 2024/8/13
Y1 - 2024/8/13
N2 - Cholera is responsible for 1.3 to 4.0 million cholera cases globally and poses a significant threat, with Zambia reporting 17,169 cases as of 4th February 2024. Recognizing the crucial link between natural cholera infections and vaccine protection, this study aimed to assess immune responses post cholera infection and vaccination. This was a comparative study consisting of 50 participants enrolled during a cholera outbreak in Zambia's Eastern Province and an additional 56 participants who received oral cholera vaccinations in Zambia's Central Province. Vibriocidal antibodies were plotted as geometric mean titres in the naturally infected and vaccinated individuals. A significant difference (p < 0.047) emerged when comparing naturally infected to fully vaccinated individuals (2 doses) on day 28 against V. cholerae Ogawa. Those who received two doses of the oral cholera vaccine had higher antibody titres than those who were naturally infected. Notably, the lowest titres occurred between 0–9 days post onset, contrasting with peak responses at 10–19 days. This study addresses a critical knowledge gap in understanding cholera immunity dynamics, emphasizing the potential superiority of vaccination-induced immune responses. We recommend post infection vaccination after 40 days for sustained immunity and prolonged protection, especially in cholera hotspots.
AB - Cholera is responsible for 1.3 to 4.0 million cholera cases globally and poses a significant threat, with Zambia reporting 17,169 cases as of 4th February 2024. Recognizing the crucial link between natural cholera infections and vaccine protection, this study aimed to assess immune responses post cholera infection and vaccination. This was a comparative study consisting of 50 participants enrolled during a cholera outbreak in Zambia's Eastern Province and an additional 56 participants who received oral cholera vaccinations in Zambia's Central Province. Vibriocidal antibodies were plotted as geometric mean titres in the naturally infected and vaccinated individuals. A significant difference (p < 0.047) emerged when comparing naturally infected to fully vaccinated individuals (2 doses) on day 28 against V. cholerae Ogawa. Those who received two doses of the oral cholera vaccine had higher antibody titres than those who were naturally infected. Notably, the lowest titres occurred between 0–9 days post onset, contrasting with peak responses at 10–19 days. This study addresses a critical knowledge gap in understanding cholera immunity dynamics, emphasizing the potential superiority of vaccination-induced immune responses. We recommend post infection vaccination after 40 days for sustained immunity and prolonged protection, especially in cholera hotspots.
KW - Cholera cases
KW - Immunity
KW - OCV
KW - Ogawa
KW - Vibrio cholerae
KW - Vibriocidal antibodies
UR - http://www.scopus.com/inward/record.url?scp=85194178880&partnerID=8YFLogxK
U2 - 10.1016/j.vaccine.2024.05.027
DO - 10.1016/j.vaccine.2024.05.027
M3 - Article
C2 - 38760271
AN - SCOPUS:85194178880
SN - 0264-410X
VL - 42
JO - Vaccine
JF - Vaccine
IS - 20
M1 - 125979
ER -